01—Abstract
Summary
Summary of the 8-K filed September 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. announced a significant leadership change with the appointment of Juan Andres as its new Chief Operating Officer (COO), effective October 5, 2026.
This is a newly created role, indicating a strategic move by Moderna to bolster its operational capabilities as it continues to scale and diversify. Mr. Andres is a familiar face, having previously held key roles at Moderna, including Chief Technical Operations and Quality Officer, where he was instrumental in scaling manufacturing for its COVID-19 vaccine. His return and appointment to this critical operational role suggest a focus on reinforcing production, supply chain, and overall business execution.
02—Key points
Key Highlights
- Juan Andres appointed as Chief Operating Officer (COO), a new executive role, effective October 5, 2026.
- Mr. Andres's prior experience at Moderna includes leading manufacturing scale-up for the COVID-19 vaccine.
- The COO role is created to support Moderna's increasing scale and diversification.
- Mr. Andres's compensation package includes an annual base salary of $800,000, an annual incentive target of 90% of base salary, and a new hire equity award valued at $5,000,000 with a four-year vesting period.
- Mr. Andres will be eligible for a future annual equity award with a target value of $4,000,000 to $5,000,000.
- Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire from the Company.
- The announcement was made via a press release furnished as an exhibit.
03—Questions
Frequently Asked Questions
What is the significance of the newly created Chief Operating Officer (COO) role?
The creation of the COO position and the appointment of Juan Andres signify Moderna's strategic intent to strengthen its operational infrastructure. This role is designed to manage and support the company's growing scale and increasingly diverse business operations, likely focusing on enhancing manufacturing, supply chain, and overall execution as Moderna advances its pipeline and commercial activities.
What is Juan Andres's background and why is his return important?
Juan Andres brings extensive relevant experience, having previously served at Moderna for nearly six years. Notably, he led the build-out and unprecedented scale-up of Moderna's manufacturing capabilities, including critical work on the COVID-19 vaccine supply chain. His deep understanding of Moderna's operational needs and his proven track record in scaling production make him a valuable asset in this new executive capacity.
What is the compensation structure for the new COO?
Juan Andres will receive an initial annual base salary of $800,000. He is also eligible for an annual cash bonus with a target of 90% of his base salary, contingent on performance. Additionally, he receives a $5,000,000 new hire equity award that vests over four years, with flexibility in its composition (stock options and/or RSUs). He will also be eligible for future annual equity awards valued between $4,000,000 and $5,000,000.
What does Jerh Collins's retirement mean for the company?
Jerh Collins, Ph.D., the current Chief Technical Operations and Quality Officer, is retiring. Given Mr. Andres's background in technical operations and quality, his appointment as COO may lead to a restructuring or reallocation of responsibilities within the operations and quality functions. Investors will want to monitor how the operational and quality oversight is managed going forward, especially with the departure of Dr. Collins and the addition of the COO role.
04—Continue